Head & Neck Cancers | Clinical

Further Research Needed to Support Use of Checkpoint Inhibitors in Locally Advanced HNSCC

May 06, 2021

Avelumab was explored in a clinical trial for the treatment of locally advanced head and neck squamous cell carcinoma, but more research is needed to position the agent and other checkpoint inhibitors in the treatment landscape, experts say.

Tipifarnib Elicits Encouraging Responses in Patients With Recurrent or Metastatic HNSCC

April 27, 2021

Results from the phase 2 study of farnesyltransferase inhibitor tipifarnib showed significant responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma and demonstrated that variant alle frequency could be a potential biomarker in this patient population.

GlaxoSmithKline Discontinues Feladilimab in Clinical Trials for Metastatic HNSCC

April 16, 2021

GlaxoSmithKline plc has announced that they will stop enrolling patients in the phase 2 INDUCE-3 and INDUCE-4 trials while simultaneously ending the use of feladilimab, originally GSK3359609, for the treatment of PD-L1-positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma after the recommendation of the Independent Data Monitoring Committee.